Orchestra BioMed Holdings (OBIO) Change in Accured Expenses (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Change in Accured Expenses for 6 consecutive years, with -$3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 1413.86% year-over-year to -$3.1 million; the TTM figure through Mar 2026 stood at $2.0 million (down 50.3% YoY), while the FY2025 annual figure was $4.9 million, up 63.89% from the prior year.
• Change in Accured Expenses fell to -$3.1 million in Q1 2026 per OBIO's latest filing, from $566000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.7 million in Q2 2024 and bottomed at -$3.1 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $486705.9 across 5 years, with a median of $566000.0 in 2025.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 8214.17% — and 2026, when it slumped 1413.86%.
• Orchestra BioMed Holdings' Change in Accured Expenses stood at $1.1 million in 2022, then tumbled by 53.4% to $493000.0 in 2023, then tumbled by 244.42% to -$712000.0 in 2024, then soared by 179.49% to $566000.0 in 2025, then slumped by 640.28% to -$3.1 million in 2026.
• Business Quant data shows OBIO's Change in Accured Expenses at -$3.1 million in Q1 2026, $566000.0 in Q4 2025, and $3.4 million in Q3 2025.